Per Jackfree's comments to Marak, you might check out my recent posting after a conversation with the investor relations people from Cypress. Obviously, this whole situation reiterates the difficulty in licensing a product like Indaflex to another company. In the end, you may get milestone payments, a nice royalty and the freedom from raising clinical trial funding but you gotta rely on the other company. In the future, perhaps ALRX will require licensees to also take an equity position in the parent company. Thus, it would be in their best interest to be timely and aggressive. I kept picturing Michael Walsh of Proprius out on the golf course in San Diego, occasionally looking for Phase 2 & 3 funding. Apparently I'm wrong about that as Cypress thought enough of him to shell out 37.5M + 20M.
I think AlphaRx has a lot of interesting products and a very bright and incredibly hard-working CEO. The rewards in these medical incubators can be massive but take time. But we need some new announcements to generate some buyers. Just not enough interest right now (remember, the PR people Lee used were only around for two months) and so thinly traded that one ongoing seller can take it down 20% in a day.....
0 members recommend this.
